Starting a Cancer Clinical Trial
The mission of the Cancer Clinical Trials Office is to conduct cancer clinical trials in a methodologically sound, safe, compliant, expedient, and cost‐effective manner, provide new technologies and treatments to patients, and advance the outcomes of translational cancer research.
Part of this mission is to provide training and standardized resources and processes for new investigators. This page was developed to help support new investigators who are interested in developing cancer clinical trials. We hope you find this collection of tools, documents and links useful. Before moving forward, please review the documents and resources below and let us know if you have any questions.
If you have any other questions starting a new trial, available resources and services, or general questions about cancer trials or the Clinical Trials Office, please contact Betty Oleson, CCCTO Administrator, or Dr. James Thomas, Medical Director. Betty can be reached at (414) 805‐8218 or firstname.lastname@example.org and Dr. Thomas can be reached at (414) 805‐4612 or email@example.com.
MCWCC Protocol Review and Monitoring System Charter (PDF) Overview of Disease Oriented Teams and Scientific Review Committee
Cancer Center Membership Information & Application Links
Cancer Center Membership Roster
Other links (PDF)
As confirmation of our strong collaboration with national cooperative groups, the MCW Cancer Center is a now a lead academic participating site in the National Clinical Trials Network (NCTN), a cooperative group program of the National Cancer Institute (NCI). Funding for these participating sites is awarded based on a site's ability to enroll high numbers of patients in NCTN trials and its scientific leadership in the design and conduct of clinical trials.
This status and participation gives MCW investigators great opportunities to open trials that will be supported by the vast resources and scientific expertise of the NCI National Clinical Trials Network. Cooperative trials allow investigators to open trials for rare cancers, or for underserved populations, or studies that require large cohorts of participants.
If you have questions about our cooperative group trials, or our role as an NCTN Lead Academic Participating Site (LAPS), please contact Jennifer Bollmer, PhD.